241 related articles for article (PubMed ID: 18591256)
1. Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias.
Kurokawa M; Zhao C; Reya T; Kornbluth S
Mol Cell Biol; 2008 Sep; 28(17):5494-506. PubMed ID: 18591256
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Wu LX; Xu JH; Zhang KZ; Lin Q; Huang XW; Wen CX; Chen YZ
Leukemia; 2008 Jul; 22(7):1402-9. PubMed ID: 18418407
[TBL] [Abstract][Full Text] [Related]
4. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
7. Loss of WD2 subdomain of Apaf-1 forms an apoptosome structure which blocks activation of caspase-3 and caspase-9.
Noori AR; Tashakor A; Nikkhah M; Eriksson LA; Hosseinkhani S; Fearnhead HO
Biochimie; 2021 Jan; 180():23-29. PubMed ID: 33132160
[TBL] [Abstract][Full Text] [Related]
8. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
9. Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Bernusso VA; Machado-Neto JA; Pericole FV; Vieira KP; Duarte AS; Traina F; Hansen MD; Olalla Saad ST; Barcellos KS
Biochim Biophys Acta; 2015 Feb; 1853(2):388-95. PubMed ID: 25450971
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-17-mediated down-regulation of apoptotic protease activating factor 1 attenuates apoptosome formation and subsequent apoptosis of cardiomyocytes.
Song S; Seo HH; Lee SY; Lee CY; Lee J; Yoo KJ; Yoon C; Choi E; Hwang KC; Lee S
Biochem Biophys Res Commun; 2015 Sep; 465(2):299-304. PubMed ID: 26265044
[TBL] [Abstract][Full Text] [Related]
12. Optimal pathways for the assembly of the Apaf-1·cytochrome c complex into apoptosome.
Qi H; Jiang Y; Yin Z; Jiang K; Li L; Shuai J
Phys Chem Chem Phys; 2018 Jan; 20(3):1964-1973. PubMed ID: 29299551
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
14. A new model for the transition of APAF-1 from inactive monomer to caspase-activating apoptosome.
Reubold TF; Wohlgemuth S; Eschenburg S
J Biol Chem; 2009 Nov; 284(47):32717-24. PubMed ID: 19801675
[TBL] [Abstract][Full Text] [Related]
15. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M
Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636
[TBL] [Abstract][Full Text] [Related]
16. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
Carroll M; Ohno-Jones S; Tamura S; Buchdunger E; Zimmermann J; Lydon NB; Gilliland DG; Druker BJ
Blood; 1997 Dec; 90(12):4947-52. PubMed ID: 9389713
[TBL] [Abstract][Full Text] [Related]
17. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
[TBL] [Abstract][Full Text] [Related]
18. Molecular insights on cytochrome c and nucleotide regulation of apoptosome function and its implication in cancer.
Yadav N; Gogada R; O'Malley J; Gundampati RK; Jayanthi S; Hashmi S; Lella R; Zhang D; Wang J; Kumar R; Suresh Kumar TK; Chandra D
Biochim Biophys Acta Mol Cell Res; 2020 Jan; 1867(1):118573. PubMed ID: 31678591
[TBL] [Abstract][Full Text] [Related]
19. Atomic structure of the apoptosome: mechanism of cytochrome c- and dATP-mediated activation of Apaf-1.
Zhou M; Li Y; Hu Q; Bai XC; Huang W; Yan C; Scheres SH; Shi Y
Genes Dev; 2015 Nov; 29(22):2349-61. PubMed ID: 26543158
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
